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1 Introduction 
 
1.1 Glioma as the most common malignant tumour occurring in the central 
nervous system  
 
Glioma is the most frequent and malignant primary intracranial tumour. According to 
the World Health Organization (WHO)’s classification, glioma is divided into I-IV 
grades. I and II grades tumours are relatively benign, while III-IV grades tumours 
belong to most malignant ones, in particular the type of Glioblastoma multiforme 
(GBM). Even with multimodal treatment encompassing surgical resection, 
chemotherapy and radiotherapy, the mean survival of patients with GBM is less than 
15 months after diagnosis (Louis et al., 2007; Nieder et al., 2006; Wong et al., 2007). 
I-II grades tumours always tend to develop into relatively higher grades ones, and the 
infiltrative nature of GBM cells makes surgical resection incomplete and patients 
relapse soon. The key biological features of its malignant phenotype are characterized 
by non-limited tumour cell growth, resistance to pro-apoptotic stimuli, 
neovascularisation and evasion of anti-tumour immune surveillance (Giese and 
Westphal, 1996; Kleihues and Cavenee, 2000). Glioma cells acquire these malignant 
properties basically due to their secretion and activation of proteases, for example, 
serine proteases and metalloproteases (MPs), which results in degrading extracellular 
matrix and breaching natural barrier to invasion and metastasis to distant sites 
(Coussens and Werb, 1996; Rao, 2003). 
 
1.2 Chemotherapy of glioma using temozolomide (TMZ) 
 
Temozolomide (TMZ) combined with surgical resection and radiotherapy is the 
standard therapy for malignant glioma, however, the acquired chemoresistance of 
glioma cells limits its effect. TMZ (8-Carbamoyl-3-methylimidazo(5,1-d) 
-1,2,3,5-tetrazin-4(3H)-one) undergoes a non-enzymatic conversion at physiologic pH 
to its active complex 5-3-(methyl)-1-(triazen-1-yl)imidazole-4-carboxamide (MTIC), 
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which is rapidly converted to the inactive 5-aminoimidazole-4-carboxamide (AIC) 
and the electrophilic alkylating methyldiazonium cation that transfers a methyl group 
to DNA (Baker et al., 1999; Villano et al., 2009). A negligible percentage (1%-2%) of 
TMZ is metabolised to TMA, which is the carboxylic acid analogue of TMZ (Baker et 
al., 1999; Tsang et al., 1990). Alkylation of the O6 position of guanine is the main 
contribution to the cytotoxic effect of TMZ. The methylated guanine mismatches with 
thymine in double-stranded DNA (O6G-T) in the first cell-cycle after the treatment, 
which induces futile cycles of mismatch repair resulting in either double strand breaks 
or a critical recombinogenic secondary lesion. The secondary lesion is considered as 
an apurinic/athymidinic site formed in faulty mismatch repair that blocks replication 
causing either DNA double strand breaks, sister chromatid exchange or other 
abnormalities (Beier et al., 2011; Kaina et al., 1997; Karran and Bignami, 1994; Ochs 
and Kaina, 2000; Roos and Kaina, 2006). Therefore, a sufficient DNA repair system is 
necessary for TMZ to exert its cytotoxic effect on tumour cells (Beier et al., 2011). 
 
 
 
Figure 1. Chemical structure of TMZ and proposed metabolism and degradation 
pathways 
*From: Baker SD, et al.(Baker et al., 1999) 
 
As a recent, oral, second generation alkylating agent, TMZ shows its efficacy for the 
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treatment of high-grade gliomas, which has been demonstrated in both pre-clinical 
and phase I- and II-studies (Dhodapkar et al., 1997; Newlands et al., 1992; O'Reilly et 
al., 1993; Stupp et al., 2002; Stupp et al., 2005; Villano et al., 2009). TMZ has 
favourable pharmacokinetic and pharmacodynamic properties. Moreover, because of 
its improved tolerability, overall survival and health-related quality of life in patients 
with malignant gliomas, TMZ appears to be an ideal, first-line, single agent for 
patients with high-grade gliomas (Villano et al., 2009). 
 
Even though TMZ combined with surgery and radiotherapy has been verified to 
prolong overall survival and improve the quality of life in patients with high-grade 
gliomas, a high prevalence of acquired resistance of glioma cells to TMZ becomes the 
major limitation in treatment of gliomas (Strik et al., 2012), which is probably due to 
intrinsic cellular chemoresistance, excessive proliferation and enhanced invasive 
ability. Understanding the underlying mechanism of the resistance is very important. 
Until now, several mechanisms of TMZ resistance were unravelled: Oliva CR. and 
colleagues (Oliva et al., 2011) reported that chemoresistance of gliomas to TMZ is 
related to a remodelling of the entire electron transport chain, with significant 
increases in the activity of complexes II/III and cytochrome C oxidase；Kitange GJ, et 
al (Kitange et al., 2009) found that resistance to TMZ in GBM is modulated by the 
status of DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT), 
and elevated MGMT protein levels or lack of MGMT promoter methylation is 
associated with TMZ resistance in glioblastoma (Kitange et al., 2009); Ulasov and 
co-workers showed that Sonic Hedgehog (SHH) and Notch pathway contribute to the 
chemoresistance of CD133+ glioma stem cells to TMZ, and their antagonism results in 
an enhanced sensitivity when used in combination with TMZ (Ulasov et al., 2011). 
 
Expression of metalloproteases has been shown to be increased in gliomas and other 
cancer types and their expression levels relate to tumour severity and malignant 
biological behaviour. We therefore presume that up-regulated metalloproteases could 
contribute to the resistance of glioma cells to temozolomide therapy. 
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1.3 Matrix Metalloproteases (MMPs) 
 
MMPs (Matrix Metalloproteases) constitute a family of zinc-dependent 
endopeptidases. About 23 MMPs are expressed in humans. The MMPs have been 
divided into collagenases, gelatinase, stromelysins and matrilysins according to their 
specificity for ECM (Extracellular Matrix) components. At present, they are 
categorised on the basis of their structure (Egeblad and Werb, 2002). Almost all 
MMPs share three common domains: the pre-domain, the prodomain, the catalytic 
peptide and the hemopexin-like C-terminal domain. MMPs are initially produced as 
an enzymatically inactive form, which is as a result of the interplay between a 
cysteine residue of the pro-peptide and the zinc-ion bound to the catalytic domain 
(“cysteine-switch”). Upon proteolytic removal of the prodomain or modification of 
the cysteine residue, the pro-MMPs are converted into active ones. Intracellular 
furin-like serine protease or some other extracellular activated MMPs as well as serine 
protease are involved in the activating process (Kessenbrock et al., 2010; Sternlicht et 
al., 1999). 
 
Figure 2. MMP domain structures 
Most MMPs share four common domains: pre-domain, prodomain, catalytic domain and 
Hemopexin domain. Furin domain for activation of MMPs. Fibronectin and Col V domains 
for substrate recognition. 
*From: McCawley LJ, et al.(McCawley and Matrisian, 2000) 
 
The activities of MMPs in vivo are controlled by the local balance between 
themselves and their physiological inhibitors. α2-Macroglobulin (α2-MG), the main 
MMPs inhibitor in tissue fluid, is produced in liver and released into plasma and then 
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binds to MMPs (Sareddy et al., 2009). The α2-MG-MMP complex is recognised by a 
scavenger receptor and irreversibly eliminated by endocytosis (Sottrup-Jensen and 
Birkedal-Hansen, 1989). The most important and best-studied endogenous inhibitors 
of MMPs are the tissue inhibitors of metalloprotease (TIMPs), which are also 
expressed in tumour lesions (Deryugina and Quigley, 2006). TIMP-1,-2,-3,-4 
reversibly inhibits MMPs in a 1:1 stoichiometric form. The expression of TIMPs is 
tissue-specific and differs in their abilities to inhibit various MMPs. Some other 
factors, like local reactive oxygen species (ROS) (Weiss et al., 1985), localization of 
MMPs (Nagase et al., 2006), also mediate MMP activation and influence their 
biological functions. 
 
MMPs play an important role in various physiological and pathological processes 
including tissue remodeling, organ development (Page-McCaw et al., 2007), 
inflammatory courses (Parks et al., 2004) and malignant diseases (Egeblad and Werb, 
2002). Historically, MMPs are mainly considered to contribute to tumour cell 
invasion and metastasis by degrading almost all components of ECM (Liotta et al., 
1980). Nowadays, mounting evidence shows that their functions are more 
complicated than initially thought (Kessenbrock et al., 2010). MMPs, as well as 
ADAMs, participate in the release of membrane-anchored latent forms of many 
growth factors (Peschon et al., 1998). MMP-2 and MMP-9 are detected to induce 
TGF-ß (transforming growth factor-ß) activation and active TGF-ß could promote 
tumour growth by stimulating angiogenesis and suppressing immune surveillance (Yu 
and Stamenkovic, 2000). MMP function may disrupt the induction of apoptosis in 
malignant cells. Liu, et al showed that MMP-7 expression could help predict the 
chemoresistance in patients with non-small cell lung cancer (Liu et al., 2008), which 
could be due to MMP-7 cleaving Fas ligand from the surface of tumour cells resulting 
in abrogating apoptosis (Mitsiades et al., 2001). MMP-1 was observed to 
proteolytically cleave PARs (protease-activated receptors), which could affect tumour 
invasion by inducing cancer cell migration (Boire et al., 2005). MMP-2, MMP-9 and 
MMP-14 are involved in tumour angiogenesis, and in fact, each MMP can contribute 
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to diverse vascular events in the tumour (Littlepage et al., 2010). Moreover, MMPs 
and ADAMs also participate in modulating the function of cytokines produced by 
immune cells and inflammation processes, which are in many aspects linked to cancer 
progression (Lin and Karin, 2007). 
 
In glioma samples, elevated expression of several MMPs, like for example MMP-1, 
MMP-2, MMP-7, MMP-9, MMP-11, MMP-12, MMP-14 and MMP-19, has been 
reported, which shows close correlation between their expression and tumour 
malignant progression in vivo (Forsyth et al., 1998; Hur et al., 2000; Stojic et al., 
2008; Tonn et al., 1999). MMP-9, MMP-2 and its activator MMP-14 have been 
demonstrated to contribute to the active migration and invasion of tumour into normal 
brain tissue (Kargiotis et al., 2008; Nakada et al., 2003). MMP-2 inhibition in glioma 
cell lines, mediated by a plasmid vector carrying siRNA against MMP-2, decreased 
radiation-induced MMP-2 expression, cell viability and radiation-enhanced cell 
migration and invasion (Badiga et al., 2011). 
 
1.4 A Disintegrin and Metalloprotease (ADAM) family 
 
Closely related to MMPs is the so-called ADAM family whose members belong to 
type I trans-membrane proteins. Until now, about forty gene members of the ADAMs 
are defined, of which only 21 are found functional in humans (Duffy et al., 2011; 
Edwards et al., 2008). The proteins share some similar domains composed of a 
prodomain, a metalloprotease domain, a disintegrin and integrin-binding domain, a 
cysteine-rich region, an EGF (epidermal growth factor)-like domain, a 
trans-membrane domain and an intracellular C-terminal domain. Similar to MMPs, 
ADAMs are also primarily produced as inactive precursor forms due to the interaction 
of a cysteine residue in the prodomain with the zinc ion at the catalytic site, and 
removal of the prodomain is prerequisite for activating the latent forms (Edwards et 
al., 2008; Murphy, 2008). ADAMs play very important roles in cell adhesion, cell 
fusion, proteolytic processing of cell trans-membrane proteins and cell signalling 
(Blobel, 2005; Duffy et al., 2009; Edwards et al., 2008; Moss and Bartsch, 2004; 
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Murphy, 2008; Stupack, 2007). They contribute to extensive physiological and 
pathological processes in accordance with the changes of their expression. Especially 
in tumour development and progression, mounting evidence indicates that ADAMs 
proteins are involved in tumour occurrence, tumour cells invasiveness, cells migration 
and proliferation (Arribas et al., 2006; Duffy et al., 2009; McGowan et al., 2008; 
McGowan et al., 2007; Peduto et al., 2006; Roemer et al., 2004). For instance, 
ADAM10 is demonstrated to promote the tumour progression by cleaving 
membrane-bound proteins including Notch molecule (Xu et al., 2010). The 
expression of ADAM9 is very low in normal epithelium of uterine cervix, but 
significantly increased in squamous cell carcinomas (SCC) of the uterine cervix 
(Zubel et al., 2009). L1CAM (CD171, a trans-membrane protein involved in cell 
adhesion, survival, growth, migration and invasion) is specifically cleaved by 
ADAM10 and Presenilin resulting in its translocation to nuclei to regulate gene 
expression, DNA damage response and radiosensitivity of glioblastoma stem cells 
(Cheng et al., 2011; Riedle et al., 2009). Compared to non-neoplastic brain tissue, the 
expression of ADAM17 is four times more increased and correlates closely to the 
malignant phenotypes of glioma cells (Zheng et al., 2012). 
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Figure 3. Structure of mature form of ADAM. 
A typical ADAM protein contains the following domains: a metalloprotease domain, a 
disintegrin domain, a cysteine-rich region, an epidermal growth factor (EGF)-like domain, a 
trans-membrane domain and a cytoplasmic domain. Additionally, latent ADAMs contain an 
N-terminal signal sequence and a prodomain, which are not shown. 
*From: Blobel CP (Blobel, 2005) 
 
ADAM8, a member of human ADAM family, is a membrane-bound protein 
composed of 824 amino acids that is coded by a gene positioned on chromosome 
10q26.3 (Hall et al., 2009). Different from typical furin-mediated activation of 
ADAMs, ADAM8 is autocatalytically activated. Similar to major amount of 
trans-membrane proteins, ADAM8 is produced as a potential form. Propeptide 
removal is necessary for the activation, and the disintegrin/cysteine-rich domain and 
metalloprotease peptide play crucial roles in the removal of prodomain (Schlomann et 
al., 2002). After removal of the prodomain, ADAM8 molecule is localized in the cell 
membrane as an active sheddase (mature form), which is further processed into a 
soluble metalloprotease and a remnant protein consisting of the DIS, Cys, EGF-like, 
TM and CD domain. The remnant form is found more abundant than the precursor 
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and mature forms in human ADAM8 (Schlomann et al., 2002). The soluble MP which 
is not inhibited by any of the TIMP proteins cleaves ECM protein consistent with the 
invasive function of ADAM8 (Ishikawa et al., 2004; Valkovskaya et al., 2007; 
Wildeboer et al., 2006). 
 
 
 
Figure 4. Structure ＆ potential functions of ADAM8 in the organism 
*From: Knolle MD, et al. (Knolle and Owen, 2009) 
 
ADAM8 is widely expressed in the immune system (Kataoka et al., 1997; Richens et 
al., 2007), bone cells (Ainola et al., 2009; Choi et al., 2001), lung (King et al., 2004), 
ovary (Sriraman et al., 2008), salivary glands, kidney (Kelly et al., 2005) and the 
central nervous system (Schlomann et al., 2000). In the central nervous system (CNS), 
ADAM8 expression is generally low, however, it is significantly increased in the 
inflamed CNS, in reactive astrocytes, oligodendrocytes, activated microglia, and in 
degenerating neurons, and exerts a neuro-protective effect (Bartsch et al., 2010; 
Mahoney et al., 2009; Schlomann et al., 2000). In several cancer types, ADAM8 has 
been shown to correlate with tumour severity and invasiveness of tumour cells. For 
instance, the expression level of ADAM8 is extensively up-regulated in glioblastoma 
tissues and consistent with the tumour progression and bleak prognosis of patients (He 
et al., 2011). Fritzsche, et al found the over-expression of ADAM8 in prostate cancer 
tissues and its highly increased expression is compatible with the dismal prognosis of 
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patients (Fritzsche et al., 2006). Wilderboer, et al observed maximal ADAM8 mRNA 
expression in glioblastoma, low-grade oligoastrocytoma and anaplastic ependymoma. 
The abundant remnant form of ADAM8 was detected in all astrocytic tumours, which 
implied that most ADAM8 molecules existed as an activated form in the tumours. 
Furthermore, invasiveness assays revealed that up-regulation of ADAM8 resulted in 
promoted migration or invasive activity of glioma cells (Wildeboer et al., 2006). 
 
1.5 Effect of presenilin (PS)/γ-secretase  
 
Since presenilin (PS)-dependent γ-secretase (PS/γ-secretase) was primarily discovered 
as an enzyme complex involved in generation of amyloid-ß (Aß), which is the main 
contributor to Alzheimer’s disease (AD), more than 90 additional proteins have been 
detected to undergo similar proteolytical processing by this enzyme (Haapasalo and 
Kovacs, 2011). PS/γ-secretase and site-2 protease (S2P), along with signal peptide 
peptidases (SPPs) and rhomboids consist of a family of intramembrane cleaving 
proteases (Weihofen and Martoglio, 2003), and they are separately responsible of 
cleaving diverse membrane-anchored proteins and involved in regulation of different 
cellular events. 
 
PS/γ-secretase is an enzyme complex with its molecular weight varying between 250 
and 2000 kDa (Haapasalo and Kovacs, 2011). In addition to presenilin, three other 
proteins have been identified as the components of active γ-secretase complex: Aph-1, 
a multipass trans-membrane protein, a type-I trans-membrane protein nicastrin and 
Pen-2, a membrane protein enhancing PS function. The four core components form 
the active PS/γ-secretase in 1:1:1:1 stoichiometry. Moreover, they are interdependent 
and interrelate with each other even though each of them has their special tasks (Sato 
et al., 2007; Spasic and Annaert, 2008; Vetrivel et al., 2006). Presenilins (presenilin-1 
and presenilin-2 encoded by PSEN1 and PSEN2, respectively) are key components of 
γ-secretase protease containing the catalytic site of the enzyme complex. 
 
Most γ-secretase substrates are type-I trans-membrane proteins and its cleaving 
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membrane-anchored proteins stubs occurs generally after the ectodomain shedding of 
full-length substrates (Struhl and Adachi, 2000). Furthermore, these substrates are 
involved in various cellular events, for example cells proliferation and apoptosis, 
adhesion, cells migration, neurite outgrowth. The intracellular domains (ICDs) of 
several substrates trans-locate into nucleus and play a role in transcriptional regulation 
of their downstream target genes after released by PS/γ-secretase. And the 
PS/γ-secretase mediated cleavage of ICDs functions as a regulatory switch in 
signalling of these special substrates. For instance, Notch family proteins regulate 
gene transcription via Notch activation and subsequent cleavage of Notch-ICD by 
γ-secretase, by which Notch proteins control cell-fate decisions and maintenance of 
stem cell populations during development (Haapasalo and Kovacs, 2011). 
PS/γ-secretase activity has also been implicated in the regulation of angiogenesis and 
tumourigenesis. Cai and colleagues found that vascular endothelial growth factor 
receptor-1 (VEGFR-1) underwent similar regulated intramembrane proteolysis (RIP) 
by γ-secretase resulting in the inhibited angiogenesis (Cai et al., 2006). Pelletier L, et 
al demonstrated that γ-secretase participate in the release of CD144-ICD leading to 
promoted cell transformation (Pelletier et al., 2006). As an important endogenous 
protease, PS/γ-secretase combined with metalloproteases (MPs) is suggested to be 
involved in DNA damage response (DDR) and an important underlying mechanism of 
the resistance of glioma cells to TMZ. 
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Figure 5. Metalloproteases (MPs) and gamma-secretase (GS) involved in processing of 
trans-membrane proteins 
MPs (ADAMs and some MMPs) and GS (γ-secretase/PS, presenilins) involved in the 
processing of trans-membrane proteins. MPs cleave the ectodomains, and afterwards, 
γ-secretase participates in the releasing of ICDs. BB-94 and DAPT function as an inhibitor of 
MPs and γ-secretase, respectively. 
 
1.6 BB-94 (Batimastat) inhibitor and DAPT inhibitor 
 
BB-94 (molecular formula: C23H31N3O4S2) is a well-known synthetic inhibitor of 
metalloproteases containing a peptide domain mimicking the cleavage site of collagen 
and a hydroxamate group, which is bound by metalloproteases and the zinc ion in the 
catalytic site of the metalloprotease, respectively. The metalloprotease is thereby 
inactivated. Since the majority of MPs share a homologous catalytic domain, BB-94 
exhibits a broad-spectrum inhibition property (Hoekstra et al., 2001) 
 
DAPT (molecular formula: C23H26F2N2O4) is widely used as a novel γ-secretase 
inhibitor, which is usually applied in research to inhibit generation of amyloid-β and 
in clinical trials to treat Alzheimer’s disease (AD). DAPT inhibits proteolytic activity 
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of γ-secretase in a non-competitive manner by an unknown mechanism. Barthet et al 
showed that DAPT stabilizes interplay between presenilin-CTF, the key component of 
γ-secretase complex, and other partner components, the APH-1/nicastrin and 
PS1-NTF/PEN-2 subcomplexes, resulting in a tensed conformation of γ-secretase 
enzyme complex. The stabilization effect of DAPT is a potential mechanism by which 
the drug regulates γ-secretase activity (Barthet et al., 2011).
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2 Aims of the study 
 
Understanding the potential molecular mechanism contributing to the resistance of 
glioma cells to the standard drug TMZ is important for optimizing existing or 
developing novel therapeutic strategies. It is reported that ADAM10 is involved in 
resistance of glioma cells by regulating L1CAM shedding that decreases 
radiosensitivity of glioblastoma stem cells (Cheng et al., 2011; Riedle et al., 2009), 
and MMP-2 inhibition sensitizes glioma cells to radiotherapy (Badiga et al., 2011). 
Furthermore, expression of metalloproteases (MPs) in glioma is remarkably 
up-regulated and associated with the malignant phenotype of glioma cells. We 
hypothesized that MPs (ADAMs and/or MMPs) contribute to resistance of glioma 
cells against TMZ by cleavage of membrane-bound proteins or increasing tumour 
cells proliferation and/or invasiveness. 
Materials 
 
23 
 
3 Materials 
 
3.1 Cell lines 
 
U87-MG glioblastoma cell line was bought from American Type Culture Collection 
(ATCC). 
 
3.2 Media and solutions for cell culture 
 
U87-MG cells were cultured in DMEM (Dulbecco’s Modified Eagle Medium) High 
Glucose (4.5g/l) supplemented with 1% L-Glutamine (200mM), 1% Penicillin/ 
Streptomycin 100×, 1mM sodium pyruvate solution, 1% MEM Non Essential Amino 
Acids 100× and 10% Fetal Bovine Serum ( heat inactivated). 
 
For activity assays, complete growth medium was exchanged into DMEM High 
Glucose (4.5g/l) without serum and phenol red on the day before collecting the 
supernatant and harvesting the cells. 
 
All materials above were bought from PAA Laboratories GmbH. 
 
3.3 Kits 
 
Description Manufacturer 
PeqGOLD Total RNA Kit 
PEQLAB Biotechnologie 
GmbH, Erlangen 
RNA to cDNA EcoDry™ Premix 
(Double Primed) 
Clontech Laboratories, Inc. 
A Takara Company 
Pierce® BCA Protein Assay Kit Thermo scientific, USA 
SuperSignal® West Femto Maximum 
Sensitivity Substrate 
Thermo scientific, USA 
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3.4 Antibodies 
 
Antibody Dilution Manufacturer 
First antibodies 
Anti-ADAM8 cytoplasmic domain 
(rabbit polyclonal) 
1:2000 Millipore, USA 
Anti-hMMP-2 affinity purified goat 
IgG 
1:1000 R&D systems 
Anti-hMMP-9 affinity purified goat 
IgG 
1:1000 R&D systems 
Anti-MMP-14 rabbit monoclonal 
antibody 
1:1000 Epitomics-Abcam 
Company, USA 
Anti-p-p44/42 MAPK (T202/Y204) 
rabbit Ab 
1:2000 Cell Signaling Technology 
Anti- ß-Tubulin (H-235) rabbit 
polyclonal 
1:500 Santa Cruz Biotechnology 
Secondary antibodies 
Anti-goat IgG, HRP-conjugated 1:2000 R&D systems 
Anti-rabbit IgG, HRP-linked antibody 1:2000 Cell Signaling Technology 
 
3.5 Protein ladder 
 
PageRuler™ Plus Prestained Protein ladder is manufactured by Pierce Biotechnology, 
Thermo Scientific, USA. 
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3.6 Buffers and Solutions 
 
Buffer and Solutions Ingredients 
Renaturing buffer 3% Triton X-100 in ddH2O 
Developing buffer 
50mM Tris PH 7.5, 200mM NaCl, 5mM CaCl2,  
0.02% Brij-35 in ddH2O 
Coomassie staining 
buffer 
50% Methanol p.A., 10% Acetic Acid,  
0.5% Coomassie Brilliant Blue in ddH2O 
Coomassie destaining 
solution 
50% Methanol p.A., 10% Acetic Acid in ddH2O 
2×Sample buffer  
(non reducing) 
2.5ml 0.5M Tris-HCl PH 6.8, 2ml Glycerol, 4ml 10% SDS, 
0.5ml 0.1% Bromphenol Blue to 10ml with ddH2O 
RIPA buffer 
50mM HEPES PH 7.4, 150mM NaCl, 1% NP-40,  
0.5% Sodium Deoxycholate,  
0.1% SDS+1×complete protease inhibitor, 1×Phosstop 
5×loading buffer 
3.125ml 1M Tris PH 6.8, 1g SDS, 4.5ml Glycerol, 125µl 
1% BPB, 1.25ml ß-Mercaptoethanol 
10×Running buffer 144g Glycine, 30g Tris Base, 10g SDS to 1L with ddH2O 
10×Transfer buffer 144g Glycine, 30g Tris Base to1L with ddH2O 
1×Transfer buffer 
(Western Blot) 
100ml 10×Transfer buffer,  
200ml Methanol to 1L with ddH2O 
5% Milk blocking 
solution 
5g no-fat dry milk powder, 100µl Tween 20,  
100ml PBS (1×) 
Substrate assay buffer 
1ml 1M Tris PH 8.0, 500µl 1M CaCl2, 50µl 1mM ZnCl2, 
1µl Brij® 35 solution to 50ml with ddH2O 
MTT solvent 5ml 1M HCl, 5ml Triton X-100, 40ml Isopropanol 
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3.7 Drugs and inhibitors 
 
Drugs and 
inhibitors 
Description 
Stock 
concentration 
Manufacturer 
Temozolomide (TMZ) 
alkylating agent for 
high-grade glioma 
100mM 
Sigma Life 
Science 
Batimastat 
broad-range 
metalloprotease 
inhibitor 
500µM 
a kind gift 
from Dr. M. 
Zack (Pfizer 
Global R&D, 
Chesterfield, 
MO, USA 
MTT 
dimethylthiazol-di
phenyl tetrazolium 
bromide 
0.5mg/ml 
Sigma Life 
Science 
DAPT 
N-[N-(3,5-difluoro
phenacetyl)-1-alan
yl]-S-phenylglycin
e t-butyl ester 
γ-secretase 
inhibitor 
10mM 
Sigma Life 
Science 
UO126 
A dual 
pERK1/ERK2 
inhibitor 
20mM 
Source 
Bioscience 
 
3.8 Oligonucleotides used for qRT-PCR 
 
All primers were synthesized by APARA-Bioscience (Freiburg, Germany) and were 
dissolved in nuclease-free water in a stock concentration of 100µM. 
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hMMP-1 fw   5’-CGG TTT TTC AAA GGG AAT AAG TAC-3’ 
hMMP-1 rev  5’-TCA GAA AGA GCA GCA TCG ATA TG-3’ 
 
hMMP-2 fw 5’-GCG GCG GTC ACA GCT ACT T-3’  
hMMP-2 rev 5’-CAC GCT CTT CAG ACT TTG GTT CT-3’ 
 
hMMP-7 fw  5’-CTG GAC GGA TGG TAG CAG TC-3’ 
hMMP-7 rev  5’-CAT ACC CAA AGA ATG GCC AAG-3’ 
 
hMMP-9 fw 5’-ACC TCG AAC TTT GAC AGC GAC-3’ 
hMMP-9 rev 5’-GAG GAA TGA TCT AAG CCC AGC-3’ 
 
hMMP-14 fw 5’-GGC TAC AGC AAT ATG GCT ACC-3’ 
hMMP-14 rev 5’-GAT GGC CGC TGA GAG TGA C-3’ 
 
hMMP-16 fw 5’-CTG CGG AAC GGA GCA GTA TTT-3’ 
hMMP-16 rev 5’-GGT AGC CGT AGT TTT GTA ACC A -3 
 
hMMP-17 fw 5’-CAC TCA TGT ACT ACG CCC TCA-3’ 
hMMP-17 rev 5’-TGG AGA AGT CGA TCT GGA TGT C-3’ 
 
XS 13 fw 5’-TGG GCA AGA ACA CCA TGA TG-3’ 
XS 13 rev 5’-AGT TTC TCC AGA GCT GGG TTG T-3’ 
 
 
hADAM8 fw 5’-ACA ATG CAG AGT TCC AGA TGC-3’ 
hADAM8 rev 5’-GGA CCA CAC GGA AGT TGA GTT-3’ 
 
hADAM9 fw 5’-TCC ATT GCT CTT AGC GAC TGT-3’ 
hADAM9 rev 5’-GGT TCA ATC CCA TAA CTC GCA T-3’ 
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hADAM10 fw 5’-ATG GGA GGT CAG TAT GGG AAT-3’ 
hADAM10 rev 5’-ACT GCT CTT TTG GCA CGC T-3’ 
 
hADAM12 fw 5’-CGA GGG GTG AGC TTA TGG AAC-3’ 
hADAM12 rev 5’-GTC CCC ACT CCC AAC AGA G-3’ 
 
hADAM17 fw 5’-GTG GAT GGT AAA AAC GAA AGC G-3’ 
hADAM17 rev 5’-GGC TAG AAC CCT AGA GTC AGG-3’ 
 
hADAM19 fw 5’-GGG AGC CTG GAT GGA CAA G-3’ 
hADAM19 rev 5’-AGC TTT GAG TGG ATG CTT TTC TC-3’   
 
3.9 qRT-PCR reagents 
 
For each well: 10µl SensiFast SYBR Hi-ROX mix (2×), 0.4µl forward primer, 0.4µl 
reverse primer, 7.2µl nuclease-free water and 2µl cDNA sample 
SYBR master mix was bought from Bioline Ltd, UK. 
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4 Methods 
 
4.1 MTT assay 
 
With cellular NAD-dependent dehydrogenase in living cells cleaving the tetrazolium 
ring, MTT (dimethylthiazol-diphenyl tetrazolium bromide) is converted into insoluble 
purple formazan crystals, which is solubilised by isopropanol and the dehydrogenase 
activity is determined spectrophotometrically by measuring absorbance at 570nm. The 
amount of the purple formazan crystal relates to the number of viable cells. The assay 
is therefore convenient and the common method for measuring viability of cells. 
 
After cells have been cultured under different conditions in 96-well plates for several 
days, medium was aspirated and 100µl MTT solution was added per well followed by 
incubation at 37oC, 5%CO2 for 4 hours. Afterwards, 100µl MTT solvent was added in 
each well to end the reaction. Pipetting up and down completely dissolved, the 
crystals and absorbance values (λ=570nm) were determined in a 96-well-plate reader 
(BMG Labtech, Offenburg, Germany). 
 
4.2 Real-time quantitative polymerase chain reaction (qPCR) 
 
The transcriptional regulation of selected genes was analysed using quantitative 
real-time PCR (Applied biosystem StepOne™ and StepOnePlus™ real-time PCR 
system). Real-time PCR (qPCR) is a method based on the detection and quantification 
of a fluorescent reporter signal that increases in direct correlation to the amount of the 
PCR product in the reaction (Lee et al., 1993; Livak et al., 1995). The cDNA was 
detected and quantified with the fluorescent dye SYBR Green, which offers a linear 
dose response over a wide range of target concentrations. As cDNA accumulates, the 
dye produces a signal that is proportional to the cDNA concentration. ROX reference 
dye was used to normalize the fluorescent signal between reactions. qPCR reactions 
were performed in 20 µl volume by using the qPCR mix. 
Methods 
 
30 
 
The program was run as follows: 
 
2-step cycling:  
Cycles Temperature Time Notes 
1 95oC 2 min 
Polymerase 
activation 
40 
95oC 
60oC 
5 s 
15 s 
Denaturation 
Annealing/extension 
 
Formation of a single specific PCR product was confirmed by melting curve analysis. 
Acidic ribosomal protein XS13 whose expression is at the same level in cells served 
as an internal concentration reference gene for all real-time PCR reactions (personal 
communication, Dr. M. Buchholz, Marburg University). Relative changes in gene 
expression were determined with the ∆Ct method using the following formula: ∆Ct = 
(Ct reference – Ct target). Differential gene expression between conditions 
corresponds to the log2 fold-difference in mRNA levels between the conditions 
compared (Livak and Schmittgen, 2001). 
 
4.3 Protein analysis 
 
4.3.1 Determination of cells number 
 
To determine the cell number of the cell suspension after trypsination, 10µl single-cell 
suspension was transferred into a Neubauer hemocytometer. The cell numbers in each 
of the outer squares were counted and averaged to obtain a mean value. The mean cell 
number was multiplied by the factor 104 to obtain the number of cells per milliliter. 
 
4.3.2 Sample preparation 
 
U87-MG cells were plated in 10cm dishes and treated with chemotherapy drugs 
and/or inhibitors for 3days, 5days and 7days, respectively. For collecting the 
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supernatants, complete culture medium was exchanged by DMEM High Glucose 
without serum and phenol red 24 hours before analysis. The conditioned DMEM was 
collected and centrifuged at 4,000 rpm for 10minutes to eliminate cell debris. Fresh 
supernatants were required for protein activity assays, while for Western Blot the 
samples were stored at -80oC before use. 
 
For preparing a protein lysate from cells, the culture medium was aspirated and RIPA 
buffer 600µl/dish was added followed by incubation at 4oC 15 minutes. Cell scrapers 
were used to collect the lysates. The samples were sonicated and centrifuged at 
13,000 rpm 5 minutes to remove the cell debris. 
 
4.3.3 BCA protein assay 
 
BCA protein assay was applied to measure the protein concentration of samples. 
Firstly, samples were diluted 1:5 and 1:10 with ddH2O and standard Bovine Serum 
Albumin (BSA) test tubes (the original Albumin solution is produced by Thermo 
Scientific with a stock concentration of 2000µg/ml) were prepared as follows: 
 
vial Volume of diluent Volume and source of BSA Final BSA concentration  
A 0 300µl of stock BSA(2mg/ml) 2000µg/ml 
B 125µl 375µl of stock BSA  1500µg/ml 
C 325µl 325µl of stock BSA 1000µg/ml 
D 175µl 175µl of vial B 750µg/ml 
E 325µl 325µl of vial C 500µg/ml 
F 325µl 325µl of vial E 250µg/ml 
G 325µl 325µl of vial F 125µg/ml 
H 400µl 100µl of vial G 25µg/ml 
 
The standard and unknown samples, along with the blank sample were added into a 
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96-well-plate in duplicate. Pierce® BCA protein assay kit was used to detect proteins 
in the samples. After incubation at 37oC for 30 minutes, the plate was read in a plate 
reader and the values for protein concentrations were obtained. 
 
4.3.4 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Proteins with different sizes were separated using SDS-PAGE, which is divided into 
non-reducing and reducing SDS-PAGE. Migration velocity of proteins in an electric 
field of proteins is proportional with their molecular weights. With samples and gel 
containing detergent SDS (sodium dodecyl sulfate) or reducing agent 
ß-mercapto-ethanol, the hydrogen bonds and disulfide bonds are broken and the 
secondary and tertiary protein structures are thereby reduced. Separated polypeptide 
chains combine with SDS, which results in proteins loaded with more negative 
charges than its original form and making all proteins moving to the positive pole in 
the electric field independent of their original shape. 
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Gel Ingredient 
Stacking 
gel 
30% Acrylamide  0.333ml 
1M Tris PH 6.8  0.25ml 
ddH2O  1.385ml 
10% SDS  20µl 
10% APS  20µl 
TEMED  2µl 
Separating 
gel 
30% Acylamide  1.667ml 
1M Tris PH 8.8  1.875ml 
ddH2O  1.364ml 
10% SDS  50µl 
10% APS  40µl 
TEMED  4µl 
For Zymography, the substrate, either 0.1% Gelatin or 1mg/ml 
Casein , was added to the gel 
 
4.3.5 Zymography assays 
 
Zymography on the basis of SDS-PAGE is used to detect the activity of native MMPs. 
Samples were prepared in non-reducing sample buffer without boiling before the 
experiment and the substrate (either Gelatin or Casein) was added in a separating gel 
to co-polymerize with polyacrylamide. During electrophoresis, proteins are separated 
in the polyacrylamide gel and meanwhile SDS in the gel keeps MMPs in an inactive 
state. After the run, gels were washed with renaturing buffer (2×30 minutes each) 
afterwards resulting in partially renatured MMPs and restored their activities. 
Subsequently, the gel was incubated in developing buffer (1×30 minutes at room 
temperature and then at 37oC in new developing buffer for 24hours) and the renatured 
MMPs in the gel digested the substrate. The next day, the gel was dyed in Coomassie 
staining buffer for 1 hour followed by Coomassie destaining solution (see page 25.), 
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so that the bands of MMPs are visualised against a blue background of undigested 
substrate. 
 
4.3.6 Western Blot 
 
Western Blot is a routine method to determine the expression status of proteins. 
Distinct from zymography assays, samples are prepared in the 5×loading buffer 
which contains detergent SDS and a reducing agent. Samples were heated at 95oC for 
10 minutes before electrophoresis. The secondary and tertiary structure of proteins are 
thereby reduced with losing their activities. After electrophoresis, separated proteins 
are transferred from the gel to a nitrocellulose membrane. Detection of target proteins 
is performed using specific antibodies (listed in 3.4 antibodies). A secondary antibody 
linked HRP (Horseradish peroxidase) is then used to cleave a chemiluminescent 
substrate and produces luminescence proportional to the amount of protein. Exposing 
the membrane to a luminescence reader (Intas, Chemostar Imager) provides an image 
of the proteins bound to the blot. 
 
4.3.7 Protease activity assays 
 
Synthetic polypeptide protein substrates have been greatly developed to estimate the 
protein activity in a real-time manner. These substrates are typically composed of a 
fluorescence resonance energy transfer (FRET) donor and a quencher fluorophore, 
which are linked by a sequence of amino acid containing a protease cleavage motif. 
Once the polypeptide is cleaved by the protease, the fluorophore donor separates from 
the quencher resulting in an increase of fluorescence. Thus, protease activity 
dynamics can be followed by tracking the changes in fluorescence over time (Moss 
and Rasmussen, 2007). 
 
Within the last 24 hours of culturing cells under different conditions, the cells were 
maintained in DMEM High Glucose without L-Glutamine and serum. Supernatants 
were freshly collected and concentrated 10:1 using VIVASPIN 4 (cutoff 10kDa, 
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Sartorius Stedim Biotech.). PEPDAB013 (Dabcyl-His-Gly-Asp-Gln-Met-Ala-Gln 
–Lys-Set-Lys(5-FAM)-NH2) and PEPDAB008 (Dabcyl-Pro-Cha-Gly-Cys(Me)His 
-Ala-Lys(5-FAM)-NH2) produced by BioZyme Inc. were used as the specific 
substrates for ADAM8 and MMP-1, respectively. The substrates were stored in 
DMSO at -20 oC in a stock concentration of 10mM. After diluting the substrates 1:500 
with substrate assay buffer, we added 20µl concentrated supernatants and 30µl 
substrate assay buffer along with 50µl diluted substrates per well in triplicate in a 
96-well-plate. For blank wells, 50µl substrate assay buffer and 50µl diluted substrate 
solution were added per well. Fluorescence was measured every 2 minutes with 
excitation and emission wavelengths of 485 and 530nm, respectively. All data were 
normalized to identical cell numbers. 
 
4.4 Invasion assay 
 
The invasion assay provides a system in vitro to assess the invasive ability of 
U87-MG cells and the changes in invasiveness could be a result of the increase of 
metalloproteases expression, which could be a potential mechanism of 
chemoresistance of glioma cells. 
 
The required number of inserts (Cell Culture Inserts 24-well 8.0µM pore size, BD 
Falcon™) were transferred into the wells of a 24-well plate with a sterile forceps and 
75µl Matrigel (MATRIGEL™ MATRIX Basement membrane Matrix, BD Bioscience) 
was carefully pipetted into each insert. The 24-well plate was then incubated at 37oC 
incubator for gelling. Cell suspension was prepared in serum-free DMEM containing 
5000 cells/300µl for each invasion chamber. 750µl complete DMEM was added into 
each lower chamber as a chemoattractant and the invasion chambers were incubated 
in a humidified tissue culture incubator at 37oC 5%CO2 atmosphere for 24 hours. A 
cotton swap was then used to remove non-invading cells. The invading-cells on the 
lower surface were fixed with 4% formaldehyde for 15 minutes and stained with 
Hematoxylin solution (Carl Roth GmbH+Co. KG Germany) at room temperature for 
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5 minutes, washed with ddH2O ( 3×10 minutes each time) and then counted under a 
light microscope. 
 
4.5 Statistical analysis 
 
All the experimental data were analysed using one-way ANOVA: Values are 
expressed as means ± SEM of n independent observations unless indicated otherwise. 
Statistical significance was evaluated by using paired student’s t-test. Only for 
evaluation of inhibitor data (UO126) a two-way ANOVA was performed. 
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5 Results 
 
5.1 Dose- and time-dependent effect of TMZ on U87-MG cells 
 
U87-MG cells were treated with different concentrations of TMZ for 3 days, 5 days 
and 7 days, respectively. After incubation with TMZ for 3 days, about 70% cells 
survived even with TMZ of high concentrations in comparison with control. However, 
after exposure to TMZ (500µM or 700µM) for 5 days, only 50% viable cells were 
detected. After long-term incubation (up to 7 days) with TMZ, there was no 
significant difference in cells survival between different concentrations of TMZ and 
when compared to control, about 30% viable cells still remained. Our results implied 
that TMZ exerts its inhibition effect on U87-MG cells in a dose- and time-dependent 
manner (Fig 6.). 
 
 
Figure 6. MTT assay to test effect of TMZ on the proliferation of U87-MG cells 
TMZ exerted its inhibition effect on U87-MG cells proliferation in a dose–dependent manner. 
However, even after long-term incubation (up to 7 days) with high concentrations of TMZ, 
there were still about 30% viable cells left. Values are presented as mean, SEM, n=3. 
Significant differences between diverse concentrations of TMZ and control (0µM) at the same 
time point, paired t-test: *p<0.05, **p<0.01. 
 
 
 
 
Results 
 
38 
5.2 Induction of metalloproteases by TMZ in U87-MG cells 
 
5.2.1 Induced expression of MPs by TMZ at mRNA level 
 
Quantitative real-time PCR was used to demonstrate that TMZ induced the expression 
of metalloproteases (ADAMs or MMPs) at mRNA level. We found that incubation 
with TMZ for 3 days has not resulted in differences in expression levels of ADAMs 
and MMPs, whereas for 5 days, TMZ caused an increased expression of ADAM8, 
MMP-1, MMP-9 and MMP-14. Compared to control, the expression of ADAM8 was 
around 14-fold increased, and the difference was significant with p＜0.01. In addition, 
MMP-1, MMP-9 and MMP-14 were around 6-fold, 5-fold and 4-fold up-regulated, 
respectively. Incubation with TMZ has not led to significant increase of expression 
levels of other MPs analysed, even for 5 days (Fig 7.). 
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Figure 7. Differences in expression levels of MPs induced by TMZ determined by 
quantitative real-time PCR analysis 
After incubation with TMZ for 3 days, no difference in expression of MPs between control 
and TMZ-treated cells was seen. Treatment of TMZ for 5 days resulted in significantly higher 
expression levels of ADAM8, MMP-1, MMP-9 and MMP-14 compared to control. Values are 
presented as mean, SEM, n=4. Significant differences, paired t-test: *p<0.05, **p<0.01, 
***p<0.001. 
 
5.2.2 Western blot of MPs induced by TMZ 
 
Western blot was employed to detect protein concentrations and the processing status 
of ADAMs and MMPs under different culture conditions. The antibody against 
ADAM8 cytoplasmic domain revealed two bands of 120 and 90 kDa, representing the 
proform and mature form of ADAM8 which is the catalytically active form. This 
active form was more abundant compared to control after treatment of TMZ (500µM) 
for 5 days, and the degree of activation, determined by the relative proportion of the 
90 kDa band to 120 kDa proform band, has been significantly enhanced after 
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treatment of TMZ, implicating that incubation with TMZ led to increased expression 
and activity of ADAM8 in U87-MG cells. MMP-14 western blot resulted in a 55kDa 
band (active form of MMP-14). Similar to the active ADAM8 band, U87-MG cells 
treated with TMZ for 5 days revealed an more intense band of MMP-14 compared to 
control. The antibody against ß-tubulin was used to normalize for protein loading. 
Concentrated supernatant of U87-MG cells under different culture conditions was 
applied to detect secreted MMP-9. The latent form of MMP-9 was found as a 92 kDa 
band. Consistent with the qPCR data, the expression level of MMP-9 in U87-MG 
cells was significantly induced after exposure to TMZ for 5 days. However, the 
expression of MMP-2, which is expressed highest in U87-MG cells among the 
surveyed MMPs in our study, was not detected to be induced by TMZ. 
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Figure 8. Western blot analysis of ADAM8, MMP-14 and MMP-9 in U87-MG cell 
protein lysate and supernatant samples, respectively 
Protein concentrations were determined using BCA protein assay and equal amount of protein 
was added in each lane. Incubation with the antibody against ß-tubulin was performed to 
determine equal protein loading for cell lysate samples. After treatment of TMZ (500µM) for 
5 days, more abundant active MMP-14 and ADAM8 and latent MMP-9 were detected in 
U87-MG cells compared to control, whereas the expression of MMP-2 has not been found 
increased. 
 
 
 
 
Results 
 
42 
5.2.3 Zymography assays demonstrating increased proteolytic activities of 
induced MMPs 
 
Zymography is considered as a very sensitive, quantifiable and functional method. It 
was used in our study to determine the activities of MMPs by identification of their 
preferential substrates and molecular weights. Gelatin zymography was mainly 
performed to detect the gelatinases MMP-2 and MMP-9. Higher expression and 
activity of MMP-9 compared to control was seen after incubation with TMZ (500µM) 
for 5 days, whereas that of MMP-2 has not been evidently changed. Casein 
zymography helped to determine the activity of MMP-1. The expression level of 
MMP-1 in U87-MG cells is normally very low (qPCR data: CT value of MMP-1 is 
about 33 cycles), so that the anti-hMMP-1 antibody hardly detects MMP-1. In the 
separating gel of Casein zymography, a more intense 48 kDa active MMP-1 band has 
been identified in the concentrated supernatant sample of U87-MG cells treated with 
TMZ (500µM) for 5 days compared to control, which revealed increased activity of 
MMP-1 after TMZ treatment. 
 
 
  
 
Figure 9. Detection of MMP activities in supernatants of U87-MG cells by Casein and 
Gelatin zymography assays 
Protein concentrations were determined using BCA protein assay and equal amount of protein 
was added in each lane. Increased expression levels and activities of MMP-1 and MMP-9 
were shown in samples of U87-MG cells treated with TMZ for 5 days. 
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5.2.4 Fluorescence activity assays for ADAM8 and MMP-1 
 
To determine the increased expression of ADAM8 and MMP-1 at mRNA/protein 
level resulting in enhanced proteolytic activity, activity assays were performed using 
concentrated supernatants of U87-MG cells under different culture conditions. 
PEPDAB013 and PEPDAB008 (BioZyme Inc.) were employed to be the specific 
substrate for ADAM8 and MMP-1, respectively. Higher activities of ADAM8 and 
MMP-1 have been found in the cell supernatant after cells exposure to TMZ (500µM) 
for 5 days in comparison to control, which revealed that TMZ could not only induce 
the expression of ADAM8 and MMP-1, but enhance their proteolytic activities as 
well. 
 
    
 
Figure 10. Activity assay determining the promoted proteolytic activities of ADAM8 and 
MMP-1 
Fluorometric analysis of protein activities for MMP-1 and ADAM8 in U87-MG cells treated 
with TMZ for 5 days showed significant mRNA/protein inductions in comparison to control. 
Activity assays were performed using specific substrates for MMP-1 and ADAM8, 
respectively. Substrate cleavage was determined by the fluorometric method and the result 
demonstrated that TMZ treatment not only induced the expression of MMP-1 and ADAM8, 
but enhanced their proteolytic activities as well. 
 
5.3 TMZ incubation enhanced invasiveness of U87-MG cells 
 
The guiding concept concerning the roles of metalloproteases in glioma has been the 
metalloproteases-mediated degradation of extracellular matrix (ECM) resulting in 
tumour cells invasion and metastasis over the past decades. To demonstrate the 
functional role of up-regulated metalloproteases in U87-MG cells after TMZ 
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treatment, we performed Matrigel™ invasion assays. When U87-MG cells were 
incubated with TMZ (500µM) for 5 days, they displayed a significantly increased 
invasive ability through Matrigel™ determined by counting the number of cells that 
migrated to the bottom of the invasion chamber. The results demonstrated clearly that 
the induction of metalloproteases in U87-MG cells by TMZ caused increased 
invasiveness of the tumour cells, which could be an essential mechanism of 
chemoresistance of malignant glioma cells. 
 
      
 
Figure 11. Invasion assay to examine the invasiveness of U87-MG cells before and after 
TMZ treatment  
A) Cells attached to the bottom of the invasion chamber stained with Hematoxylin have been 
found under bright-field microscopy. B) Relative numbers of invaded U87-MG cells were 
counted in randomly selected viewing fields. After TMZ treatment, much more cells migrated 
through the Matrigel™ showing promoted invasive ability of U87-MG cells compared to 
control. Values are presented as mean, SEM, n=5. Significant differences, paired t-test: 
**p<0.01. 
 
5.4 Effect of BB-94（Batimastat）on U87-MG cells treated with TMZ  
 
5.4.1 BB-94 sensitizes U87-MG cells to TMZ using MTT assay 
 
The data above demonstrated that the up-regulated expression levels and activities of 
some metalloproteases caused by TMZ could be involved in the mechanism of 
A B 
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chemoresistance of glioma cells, therefore, inhibition of these metalloproteases could 
result in promoted sensitivity of U87-MG cells to TMZ. To analyse that, we used the 
broad-spectrum MP inhibitor (BB-94), which is capable of inhibiting MMP-1 
(IC50=3nM), MMP-9 (IC50=4nM), MMP-14 (IC50=2.1nM) and ADAM8 
(IC50=51.3nM). 
 
We performed MTT assays using BB-94 (0.02µM) to co-incubate U87-MG cells with 
TMZ (500µM). After incubation for 3 days, almost no difference in the percentage of 
viable cells has been found between two groups with and without BB-94. However, 
around 20% less viable U87-MG cells remained when treated for 5 days with BB-94 
and TMZ compared to the group without BB-94 (55% versus 75%). A smaller 
difference was seen in U87-MG cells cultured for 7 days (25% versus 35%). 
Real-time PCR analysis showed that after TMZ treatment for 5 days, expression 
levels of ADAM8, MMP-1, MMP-9 and MMP-14 in U87-MG cells were found 
significantly increased. This MTT assay also revealed a notable difference in cell 
viability after incubation with TMZ for 5 days. These data suggest that the 
up-regulated metalloproteases result in enhanced proliferation of malignant glioma 
cells and inhibition of these proteases causes decreased proliferation and increased 
sensitivity of tumour cells to TMZ. 
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Figure 12. MTT assay to examine chemosensitivity of U87-MG cells caused by inhibition 
of metallproteases 
BB-94 was used to inhibit the activities of metalloproteases. It was revealed that BB-94 in 
combination with TMZ led to less viable tumour cells remaining compared to cells treated 
with TMZ alone. Values are presented as mean, SEM, n=6. paired t-test: **p<0.01, 
***p<0.001. 
 
5.4.2 BB-94 offsets the promoted invasiveness of U87-MG cells by TMZ 
 
Invasion assays were performed to determine the lowered invasive ability of U87-MG 
cells caused by BB-94 incubation. U87-MG cells alone don’t show any invasive 
ability through Matrigel™, however, TMZ significantly increased invasiveness of 
U87-MG cells judged by the number of cells migrated to the bottom of invasion 
chambers in our study. Using BB-94 to inhibit the function of metalloproteases 
resulted in very low migration rate through Matrigel™.These results verified properly 
our hypothesis mentioned above, that is, the up-regulation of metalloproteases 
resulting in increased proliferation and invasiveness of malignant glioma cells is an 
important aspect involved in the chemoresistance of glioma cells, which could be 
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overcome by inhibition of these endogenous peptidases. 
 
      
 
Figure 13. Inhibited invasiveness of U87-MG cells caused by BB-94 
A) Invading cells attached to the bottom of invasion chambers under a light microscope. B) 
Relative numbers of invading cells were counted in randomly selected viewing fields. BB-94 
lowered the invasive ability of U87-MG cells effectively. Values are presented as mean, SEM, 
n=6. Significant differences, paired t-test: ***p<0.001. 
 
5.5 Effect of TMZ on intracellular ERK signalling 
 
5.5.1 UO126 partly counteracts TMZ-induced MPs 
 
Mitogen-activated protein kinases [MAPKs, also called extracellular signal-regulated 
kinases (ERKs)] constitute a signal cascade transduction pathway from cell surface to 
nucleus, which participates in a variety of cellular events, from embryogenesis and 
differentiation to cell proliferation and death. To determine that MAPKs pathway 
serves as an essential machinery underlying the induction of MPs by TMZ, UO126 
was applied to inhibit ERK1/ERK2 pathway and helped find the potential effect of 
MAPKs signalling on the increased expression of MPs. We treated U87-MG cells 
with UO126 of 10µM in combination with TMZ (500µM) for 5days and harvested the 
cells. Western blot was used to determine the inhibitory effect of UO126 on activation 
of ERK1/ERK2 (Fig 14.). In comparison to control, cells treated with TMZ displayed 
A B 
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enhanced active ERK1/ERK2, whereas UO126 blocked this activity of TMZ. 
ß-Tubulin was used to provide a loading comparison. Real-time PCR has been 
performed to demonstrate the suppressive influence of UO126 on the expression of 
MPs at mRNA level (Fig 15.). The induced expression of ADAM8, MMP-1 and 
MMP-9 by TMZ has been significantly decreased by UO126 incubation and the 
lowered expression approached baseline expression of these MPs in U87-MG cells. 
However, UO126 has not counteracted the increased expression of MMP-14, and 
even slightly enhanced the induced expression of MMP-14 by TMZ. 
 
 
Figure 14. Western blot to analyse the effect of UO126 on the activation of pERK1/2. 
After incubation with TMZ for 5 days, expression of activated ERK1/2 in U87-MG cells was 
increased. However, UO126 reversed the induction of pERK by TMZ. 
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Figure 15. Real-time PCR to demonstrate influence of UO126 on the expression of 
induced MPs by TMZ 
UO126 significantly decreased the up-regulated expression of ADAM8, MMP-1 and MMP-9 
by TMZ. The promoted expression of MMP-14 was not offset by UO126, but slightly 
enhanced. Values are presented as mean, SEM, n=6. Significant differences, paired t-test: 
**p<0.01, ***p<0.001. 
 
5.5.2 Effect of UO126 on the chemoresistance and invasiveness of U87-MG cells 
 
Given that UO126 has been shown to reverse the increased expression of ADAM8, 
MMP-1 and MMP-9, we further performed MTT assays and invasion assays to detect 
its influence on the malignant phenotype of U87-MG cells. MTT assays demonstrated 
that UO126 caused rising sensitivity of U87-MG cells to TMZ. When compared to the 
group with TMZ treatment alone, about 5% less viable cells remained after incubation 
with UO126 and TMZ for 5 days (Fig 16.). Inhibition of MAPK pathway resulted in 
significantly decreased invasiveness of U87-MG cells (Fig 17.). 
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Figure 16. MTT assay to examine the effect of UO126 on the susceptibility of U87-MG 
cells to TMZ 
In comparison to cells without UO126 treatment, UO126 incubation results in about 5% less 
viable cells remaining. Values are presented as mean, SEM, n=3. paired t-test: **p<0.01. 
 
 
     
 
Figure 17. Invasion assay to survey effect of UO126 on the invasiveness of U87-MG cells 
UO126 offset the increased invasiveness of U87-MG cells caused by TMZ. A) Images of 
invading cells attached to the lower side of invasion chambers. B) Relative numbers of 
invading cells were counted in randomly selected viewing fields. Values are presented as 
mean, SEM, n=6. Significant differences, paired t-test: ***p<0.001. 
 
5.6 DAPT decreases the resistance of U87-MG cells towards TMZ 
 
PS/γ-secretase combined with metalloproteases (MPs) are involved in a variety of 
trans-membrane proteins activation and signalling pathways. To investigate the 
involvement of γ-secretase in conferring chemoresistance, MTT assays were 
performed using DAPT (1µM) as an inhibitor of γ-secretase. U87-MG cells were 
A B 
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cultured for 5 days and the data showed that DAPT+TMZ caused about 6% less 
viable cells compared to treatment of TMZ alone (Fig 18.), which indicated that 
γ-secretase was also associated with the resistance of U87-MG cells towards TMZ. 
 
Figure 18. MTT assay to determine the role of γ-secretase in the resistance of U87-MG 
cells against TMZ 
Incubation with DAPT, an inhibitor of PS/γ-secretase, caused 6% less viable cells remaining. 
Values are presented as mean, SEM, n=6. Significant differences, paired t-test: *p<0.05. 
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6 Discussion 
 
Despite great advantages in treatment strategies developed over the past decades, the 
long-term survival rate of patients with glioblastoma remains very low and this 
tumour type is still a major challenge in the field of neurosurgery (Torres et al., 2011). 
TMZ is a second-generation alkylating agent widely applied to treat malignant glioma 
(Villano et al., 2009). Acquired resistance of glioma cells to TMZ limits its efficacy 
(Kitange et al., 2009; Oliva et al., 2011; Strik et al., 2012; Ulasov et al., 2011). This 
study was encouraged by recent observations that the cell adhesion L1 is up-regulated 
under irradiation conditions and interferes after MP-mediated proteolytic cleavage 
with the DNA Damage Response machinery (Cheng et al., 2011). Therefore, our study 
aims to explore a potential contribution of metalloproteases to chemoresistance of 
glioblastoma upon TMZ treatment. 
 
A Disintegrin And Metalloprotease (ADAM) family and Matrix Metalloproteases 
(MMPs) are well known endogenous metalloproteases, which bind a Zn2+ ion in the 
active site and catalyze the hydrolysis of non-terminal peptide bonds (Creighton, 
1993). They play important roles in various physiological processes and pathogenesis 
or progression of cancers. It is shown that these metalloproteases are increased in 
many types of tumours and contribute to almost all aspects of malignant phenotype of 
cancers. In glioma specimens, elevated expression of ADAM and MMPs are as well 
involved in the proliferation, migration, neovascularisation, invasion and 
radioresistance of tumour cells. We hypothesized therefore that increased expression 
of metalloproteases also contributes to chemoresistance of glioma cells to TMZ. 
 
In our study, TMZ was found to exert its inhibitory effect on U87-MG cells in a dose- 
and time-dependent manner (Fig 6.). After relative short-term incubation (3 days) 
with TMZ in increasing concentrations, 500µM TMZ revealed a significant 
suppressive effect with only 75% viable cells remaining, whereas TMZ of ≤200µM 
showed a weak effect compared with control. However, after incubation with TMZ 
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for 5 or even 7 days, a remarkable decrease in surviving cells was detected even with 
TMZ at lower concentrations. The mechanism by which TMZ acts on the cells (DNA 
damage and induction of DDR) is expected to be a long-term effect. At present, two 
groups of alkylating agents are used to treat cancers (TMZ and so-called CNUs) 
(Beier et al., 2011). Different from CNUs, TMZ needs a sufficient DNA repair system 
to be effective, and it is the tertiary lesions formed during faulty mismatch repair, not 
the primary lesions caused by TMZ that induces cell death of affected tumour cells 
(Beier et al., 2011). Roos and co-workers also showed that TMZ-induced and 
dose-dependent apoptosis in glioma cells occurred at late time points starting after 
72-96 hours (Roos et al., 2007). In addition, it is demonstrated that even with 
long-term incubation with TMZ of high concentrations, about 30% U87-MG cells 
survive in our study, which indicates that in addition to causing apoptosis, TMZ has 
also a cytostatic effect on tumour cells. Hermisson and colleagues described a similar 
result that even high concentrations of TMZ (up to 1290µM) led to up to 40% 
surviving glioma cells (Hermisson et al., 2006). 
 
Sequentially, we surveyed changes in expression levels of metalloproteases caused by 
TMZ. As a long-term expression change, we observed up-regulation of MMP-1, -9, 
-14 and ADAM8 at mRNA, protein and activity level after U87-MG cells have been 
treated with TMZ (500µM) for 5 days. At mRNA level, expression levels of these 
MPs were 6-fold, 5-fold, 4-fold and 14-fold increased, respectively (Fig 7.). However, 
some other MPs, even MMP-2, ADAM10 and ADAM17 expressed in glioma in 
significantly high expression, were not detected to be induced by TMZ. Protein 
analyses including Western blot, zymography assays and activity assays were 
employed to demonstrate the elevated expression and proteolytic activities of the MPs 
caused by TMZ (Fig 8., 9., and 10.). MMP-1, which is not substantially expressed in 
normal brain tissue, has been found elevated in glioma cells (Hodgson et al., 2009) 
and corresponds to tumour severity and survival time of patients (Stojic et al., 2008). 
MMP-9 is one of the two most abundant MMPs found in gliomas (Hormigo et al., 
2006; Komatsu et al., 2004; Nakada et al., 2003) and involved in tumour biology 
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(Ezhilarasan et al., 2009; Lakka et al., 2002). MMP-14 has as well been demonstrated 
to be over-expressed in gliomas and contribute to the active migration and invasion of 
tumour into normal brain tissue (Nakada et al., 2003; Van Meter et al., 2004). 
Furthermore, ADAM8 is highly regulated in gliomas and its expression level is 
associated with invasiveness (Wildeboer et al., 2006). All together, these induced MPs 
by TMZ play important roles in malignant behaviour of gliomas, which makes us 
consider that they could probably be involved in the chemoresistance. 
 
BB-94, serving as a broad-spectrum inhibitor of metalloproteases, was used in our 
study to demonstrate inhibition of MPs resulting in increased sensitivity of glioma 
cells to TMZ therapy. BB-94 combined with TMZ led to increased apoptosis of 
U87-MG cells in comparison to another group without BB-94 incubation after we 
treated the cells for 5 days or 7days (Fig 12.), whereas for 3 days, no significant 
distinction was detected between the two groups. We therefore assume that it is the 
up-regulated MPs that contribute to the resistance when integrating this result with the 
data of qPCR and protein analyses, and inhibition of these MPs causes susceptibility 
of U87-MG cells to TMZ. When comparing the percentage of remaining viable cells 
between the two groups, around 20% difference was shown. However, Devy et al 
described that specific inhibition of MMP-14 activity yielded no less than 70% 
tumour growth inhibition in breast cancer xenograft mouse models in which MMP-14 
was over-expressed (Devy et al., 2009). Our understanding of the hydroxamate-based 
inhibitor BB-94 is still far from complete. It is not a selective inhibitor for a certain 
MP and it is reported that ADAM proteases are not inhibited specifically by BB-94 
(Koller et al., 2009). Therefore, BB-94 is not considered as an ideal agent to inhibit 
functions of MPs and specific inhibitors are promising and becoming the focus of 
cancer research (Zucker and Cao, 2009). Nevertheless, the promoted susceptibility of 
U87-MG cells to TMZ via inhibition of MPs by BB-94 implicates that induced 
expression of MPs contributes to the resistance of glioma cells to TMZ. 
 
Invasion assays demonstrated that up-regulated expression of ADAM8, MMP-1, 
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MMP-9 and MMP-14 by TMZ causes promoted invasiveness of U87-MG cells, 
which was in turn suppressed by an inhibitor of MPs, BB-94 (Fig 11,13). As 
mentioned above, BB-94 does not work specifically on ADAMs, therefore increased 
MMPs caused by TMZ are considered as the main contributors to enhanced 
invasiveness. Inhibition of these MPs results in lowered invasive ability of U87-MG 
cells. Since TMZ is a standard therapy for glioma, the increased expression of MPs 
causes enhanced invasiveness as a response of glioma cells to TMZ leading to tumour 
cells invading surrounding normal brain tissues and is therefore a critical machinery 
underlying the chemoresistance and recurrent tumour formation. In agreement with 
this hypothesis, we found in a proteomic screening (in collaboration with Dr. Oliver 
Schilling, Freiburg University) comparing U87-MG cells (TMZ) with U87-MG cells 
(TMZ+BB-94) that BB-94 prevents shedding of CD44 from U87-MG cells treated 
with TMZ (data available on request). Since CD44 (hyaluronic acid receptor) is 
crucial for glioma migration and invasiveness, we conclude that the BB-94 effect on 
invasiveness could at least in part be due to lack of cleavage of CD44. Other potential 
candidates found in the proteomic screening are Met (HGF/SF, Scatter factor) and 
integrins β1 and αv, all of which could contribute to invasiveness of glioma cells.  
 
In our study, we have employed other glioma cell lines, like for example U373, U251 
and G28, to demonstrate the similar mechanism involved in the chemoresistance (data 
not shown). We found that using BB-94 of indicated concentration sensitized these 
glioma cells to TMZ as well, demonstrating that up-regulated MPs by TMZ are also 
involved in the resistance against TMZ in some other glioma cell lines. 
 
The upregulation of MMP-2, MMP-9 and MMP-14 and their role in invasiveness has 
been described earlier (Gabelloni et al., 2010; Trog et al., 2006), however, no data in 
the use of BB-94 and on the mechanism of MMP regulation was provided in these 
reports. 
 
It was also reported that in T98G glioblastoma multiforme (GBM) cell, epidermal 
growth factor (EGF) induces MMP-1 expression mainly via MAPK pathway (Anand 
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et al., 2011). Xie H and co-workers showed that up-regulated expression levels of 
MMP-7 and MMP-14 were associated with the increasing pathological grades in brain 
glioma tissues and UO126 significantly decreased the expression of MMP-7 and 
MMP-14 in U87-MG cells (Xie et al., 2011). In our study, we also presume that TMZ 
induces the expression of ADAM8, MMP-1, MMP-9 and MMP-14 via MAPK 
pathway. We examined the effect of ERK1/ERK2 inhibitor on the expression of these 
induced MPs and sensitivity of U87-MG cells to TMZ. Our results demonstrated that 
TMZ induced expression of MPs in part via MAPK pathway, as UO126 decreased the 
TMZ-induced expression of ADAM8, MMP-1 and MMP-9 which contributed mainly 
to enhanced invasiveness of U87-MG cells. Furthermore, UO126 sensitized U87-MG 
cells to TMZ. However, UO126 exerted almost no effect or even a positive effect on 
the expression of MMP-14, which implicates that a more complex regulation of 
MMP-14 independent from ERK1/2 signalling after TMZ treatment. 
 
Metalloproteases mainly contribute to shedding of ectodomains of a majority of 
membrane-bound proteins resulting in activation of these proteins, and subsequently, 
PS/γ-secretases are involved in releasing the remaining intracellular domains (ICDs) 
which play a role in a variety of cellular events. DAPT, an inhibitor of γ-secretase, 
was used to examine the impact of γ-secretase on the resistance of glioma cells to 
TMZ. Our data showed that DAPT promoted the sensitivity of U87-MG cells to TMZ 
treatment, which implicates that PS/γ-secretase has also an important role in the 
resistance of glioma cells to chemotherapy. Several trans-membrane proteins, for 
example Notch protein, EGF (epidermal growth factor) and NCAM-L1 (neural cell 
adhesion molecule L1) (Shah et al., 2005), are likely to be the target proteins of the 
endogenous peptidases and confer the chemoresistance of glioma cells. Gilbert et al 
found that DAPT decreased chemoprotection and repopulation of TMZ-treated 
gliomas via Notch pathway and DAPT+TMZ treatment in vivo blocked significantly 
tumour progression (Gilbert et al., 2010). Therefore, the results indicate that the 
induced MPs cause the resistance of glioma cells towards TMZ probably via cleaving 
some trans-membrane proteins involved in DNA damage response (DDR) or 
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promoting proliferation and invasiveness of glioma cells. 
 
In conclusion, we find that metalloproteases play a crucial role in the resistance of 
glioma cells against TMZ which is a standard agent treating gliomas. It is revealed 
that TMZ incubation not only induces the expression of MMP-1, MMP-9, MMP-14 
and ADAM8, but enhances their proteolytic activities as well. BB-94 serving as a 
broad-spectrum inhibitor of MPs in combination with TMZ leads to more apoptosis of 
U87-MG cells, that is, sensitizes U87-MG cells to TMZ. Furthermore, the promoted 
invasiveness of U87-MG cells by TMZ is also inhibited by BB-94. TMZ induces the 
expression of MPs partly via MAPK pathway. Inhibition of PS/γ-secretase also leads 
to increased susceptibility of glioma cells to TMZ. 
 
Here we show that induction of MPs by TMZ is an important aspect that contributes 
to the chemoresistance of glioma cells by cleaving some membrane-anchored proteins 
participating in DDR or increasing proliferation and invasiveness of glioma cells, 
which in future therapy regimens could be overcome by the specific inhibition of MPs 
to prevent formation of recurrent glioma. 
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7. Summary 
 
7.1 Summary 
 
Glioblastoma multiforme (GBM) is the most malignant type of brain tumours bearing 
a grim prognosis with a median survival of 14.8 months. Despite therapeutic advances 
over the past decades, GBM treatment remains ineffective with temozolomide (TMZ) 
as a standard chemotherapeutic agent. Even using TMZ combined with surgical 
resection and radiotherapy, the 2-year survival for patients of high-grade gliomas 
remains very low. Understanding potential molecular mechanisms contributing to the 
resistance of glioma cells to TMZ is important for optimizing the existing and 
developing novel therapeutic strategies. 
 
Metalloproteases (MPs) have been found to be increased in GBM and are associated 
with the malignant phenotype. In our study, we have systematically examined the 
changes in the expression of MPs in U87-MG cells after TMZ treatment and found 
that treatment of U87-MG glioblastoma cells with TMZ for at least 5 days induces 
expression of metalloproteases ADAM8, MMP-1, MMP-9 and MMP-14 in surviving 
U87-MG cells.  
 
To analyse the function of these MPs, a broad-spectrum metalloprotease inhibitor 
batimastat (BB-94) was applied to U87-MG cells in conjunction with TMZ. BB-94 
causes increased susceptibility of U87-MG cells to TMZ induced cell death and 
reduces the invasive potency of U87-MG cells, indicating that the induction of MPs 
by TMZ contributes to chemoresistance and recurrence of glioblastoma. As a potential 
mechanism of MP induction by TMZ we found that ERK1/2 phosphorylation in 
U87-MG cells is enhanced after TMZ treatment. Application of UO126, a specific 
ERK1/2 inhibitor, abrogates TMZ-induced expression of ADAM8, MMP-1 and 
MMP-9, but not of MMP-14, implicating that there are alternative pathways for the 
induction of MMP-14 by TMZ.  
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PS/γ-secretase combined with MPs participates in trans-membrane processing of 
numerous proteins thereby regulating various intracellular pathways. Inhibition of 
γ-secretase using DAPT had a similar effect as BB-94 on sensitization of U87-MG 
cells to TMZ, suggesting that γ-secretase could function as an adjuvant peptidase to 
MPs to be involved in the chemoresistance of glioblastoma cells. 
 
Taken together, we conclude that the induction of particular MPs MMP-1, MMP-9, 
MMP-14, and ADAM8 by TMZ causes chemoresistance of glioblastoma cells, and 
these MPs confer chemoresistance via cleaving membrane-bound proteins, for 
example CD44, Met or integrins ß1 and/or αv, which might be involved in DNA 
damage response (DDR) or in proliferation and invasiveness of tumour cells. 
Therefore, TMZ treatment combined with MP inhibitor appears as a feasible therapy 
option to optimize TMZ therapies and to prevent recurrent glioma formation. 
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7.2 Zusammenfassung 
 
Glioblastoma Multiforme (GBM) ist der aggressivste hirneigene Tumor mit einer 
schlechten Überlebensprognose. Trotz Weiterentwicklung der multimodalen 
Behandlungsansätze, bestehend aus Tumorresektion und Radio- sowie Chemotherapie 
ist die Therapie des GBM bei einem durchschnittlichen Überleben von 2 Jahren nur 
bedingt erfolgreich. Als Standardchemotherapie kommt heutzutage das alkylierende 
Chemotherapeutikum Temozolomid (TMZ, Temodal®) zum Einsatz. Ein Grund für 
die ineffiziente Wirksamkeit von Chemo-und Radiotherapie ist die Ausbildung von 
Resistenzen in den Tumorzellen. Das Verständnis der Resistenzbildung auf 
molekularer Ebene ist daher sehr wichtig und könnte neue Ansätze zur Optimierung 
der Chemo- und Radiotherapie liefern. 
 
Metalloproteasen (MPs) sind in GBMs erhöht exprimiert und stets mit einer 
schlechten Prognose verbunden. In dieser Studie haben wir die Expression von MPs 
nach TMZ-Behandlung in U87-MG Glioblastom-Zellen systematisch untersucht. Eine 
TMZ-Behandlung von 5 Tagen induziert in U87-MG Zellen eine erhöhte Expression 
von ADAM8, MMP-1, MMP-9 and MMP-14 in den überlebenden Zellen. 
 
Um die Funktion der induzierten MPs zu untersuchen, wurde der Breitband 
MP-Inhibitor Batimastat (BB-94) in U87-MG Zellen in Verbindung mit TMZ 
eingesetzt. BB-94 führt zu einer erhöhten Sensitivität von U87-MG Zellen gegenüber 
dem TMZ-induzierten Zelltod und verringert das durch TMZ induzierte invasive 
Potenzial von U87-MG Zellen. Daraus folgt, dass die durch TMZ induzierten MPs 
sowohl zu einer Chemoresistenz als auch zu einer Rezidiv-Bildung beitragen können. 
Als potenzieller Signalweg der TMZ-vermittelten MP-Induktion in U87-MG Zellen 
wurde eine Zunahme der ERK1/2 Phosphorylierung unter TMZ-Behandlung 
nachgewiesen. Die Verwendung des ERK1/2 Inhibitors UO126 führte zu einer 
Abnahme der TMZ-induzierten Expression von ADAM8, MMP-1 and MMP-9, aber 
nicht von MMP-14, was darauf hindeutet, dass es alternative Signalwege bei der 
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Induktion von MMP-14 gibt. 
 
PS/γ-Sekretase kombiniert mit MPs führt zu einer Prozessierung von 
Transmembran-Proteinen, durch die zahlreiche intrazelluläre Signalwege gesteuert 
werden. Die Inhibition von γ-Sekretase durch DAPT hat in unseren Analysen einen 
vergleichbaren Effekt wie BB-94 auf die Sensitivierung von U87-MG Zellen durch 
TMZ, was darauf schließen lässt, dass γ-Sekretase zusammen mit MPs zu einer 
Chemoresistenz von Glioblastom-Zellen führen kann. 
 
Zusammenfassend lässt sich sagen, dass die Induktion der Metalloproteasen MMP-1, 
MMP-9, MMP-14, and ADAM8 durch TMZ eine Chemoresistenz von 
Glioblastom-Zellen vermitteln kann und dass diese Metalloproteasen durch die 
Spaltung von Membranproteinen wie z.B. CD44, Met oder Integrinen an der „DNA 
Damage Response“ beteiligt sind oder die Proliferation und die Invasivität von 
Glioblastom-Zellen fördern können. Deshalb wäre eine kombinierte Therapie von 
TMZ mit Metalloprotease-Inhibitoren eine mögliche Therapie-Option, um die 
Effizienz der Standard-TMZ-Therapie zu verbessern und die Rezidivneigung  zu 
verhindern. 
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